IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection

Jason Beiko, Dima Suki, Kenneth R. Hess, Benjamin D. Fox, Vincent Cheung, Matthew Cabral, Nicole A Shonka, Mark R. Gilbert, Raymond Sawaya, Sujit S. Prabhu, Jeffrey Weinberg, Frederick F. Lang, Kenneth D. Aldape, Erik P. Sulman, Ganesh Rao, Ian E. Mccutcheon, Daniel P. Cahill

Research output: Contribution to journalArticle

158 Citations (Scopus)

Abstract

BackgroundIDH1 gene mutations identify gliomas with a distinct molecular evolutionary origin. We sought to determine the impact of surgical resection on survival after controlling for IDH1 status in malignant astrocytomas - World Health Organization grade III anaplastic astrocytomas and grade IV glioblastoma.MethodsClinical parameters including volumetric assessment of preoperative and postoperative MRI were recorded prospectively on 335 malignant astrocytoma patients: n = 128 anaplastic astrocytomas and n = 207 glioblastoma. IDH1 status was assessed by sequencing and immunohistochemistry.ResultsIDH1 mutation was independently associated with complete resection of enhancing disease (93% complete resections among mutants vs 67% among wild-type, P <. 001), indicating IDH1 mutant gliomas were more amenable to resection. The impact of residual tumor on survival differed between IDH1 wild-type and mutant tumors. Complete resection of enhancing disease among IDH1 wild-type tumors was associated with a median survival of 19.6 months versus 10.7 months for incomplete resection; however, no survival benefit was observed in association with further resection of nonenhancing disease (minimization of total tumor volume). In contrast, IDH1 mutants displayed an additional survival benefit associated with maximal resection of total tumor volume (median survival 9.75 y for >5 cc residual vs not reached for <5 cc, P =. 025).ConclusionsThe survival benefit associated with surgical resection differs based on IDH1 genotype in malignant astrocytic gliomas. Therapeutic benefit from maximal surgical resection, including both enhancing and nonenhancing tumor, may contribute to the better prognosis observed in the IDH1 mutant subgroup. Thus, individualized surgical strategies for malignant astrocytoma may be considered based on IDH1 status.

Original languageEnglish (US)
Pages (from-to)81-91
Number of pages11
JournalNeuro-Oncology
Volume16
Issue number1
DOIs
StatePublished - Jan 1 2014

Fingerprint

Astrocytoma
Survival
Glioblastoma
Glioma
Mutation
Immunohistochemistry
Genotype
Genes
Neoplasms

Keywords

  • IDH1
  • anaplastic astrocytoma
  • glioblastoma
  • malignant glioma
  • surgical resection

ASJC Scopus subject areas

  • Oncology
  • Clinical Neurology
  • Cancer Research

Cite this

IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection. / Beiko, Jason; Suki, Dima; Hess, Kenneth R.; Fox, Benjamin D.; Cheung, Vincent; Cabral, Matthew; Shonka, Nicole A; Gilbert, Mark R.; Sawaya, Raymond; Prabhu, Sujit S.; Weinberg, Jeffrey; Lang, Frederick F.; Aldape, Kenneth D.; Sulman, Erik P.; Rao, Ganesh; Mccutcheon, Ian E.; Cahill, Daniel P.

In: Neuro-Oncology, Vol. 16, No. 1, 01.01.2014, p. 81-91.

Research output: Contribution to journalArticle

Beiko, J, Suki, D, Hess, KR, Fox, BD, Cheung, V, Cabral, M, Shonka, NA, Gilbert, MR, Sawaya, R, Prabhu, SS, Weinberg, J, Lang, FF, Aldape, KD, Sulman, EP, Rao, G, Mccutcheon, IE & Cahill, DP 2014, 'IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection', Neuro-Oncology, vol. 16, no. 1, pp. 81-91. https://doi.org/10.1093/neuonc/not159
Beiko, Jason ; Suki, Dima ; Hess, Kenneth R. ; Fox, Benjamin D. ; Cheung, Vincent ; Cabral, Matthew ; Shonka, Nicole A ; Gilbert, Mark R. ; Sawaya, Raymond ; Prabhu, Sujit S. ; Weinberg, Jeffrey ; Lang, Frederick F. ; Aldape, Kenneth D. ; Sulman, Erik P. ; Rao, Ganesh ; Mccutcheon, Ian E. ; Cahill, Daniel P. / IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection. In: Neuro-Oncology. 2014 ; Vol. 16, No. 1. pp. 81-91.
@article{5fb3fc8c1e9e4baf8c7fb495016c18e3,
title = "IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection",
abstract = "BackgroundIDH1 gene mutations identify gliomas with a distinct molecular evolutionary origin. We sought to determine the impact of surgical resection on survival after controlling for IDH1 status in malignant astrocytomas - World Health Organization grade III anaplastic astrocytomas and grade IV glioblastoma.MethodsClinical parameters including volumetric assessment of preoperative and postoperative MRI were recorded prospectively on 335 malignant astrocytoma patients: n = 128 anaplastic astrocytomas and n = 207 glioblastoma. IDH1 status was assessed by sequencing and immunohistochemistry.ResultsIDH1 mutation was independently associated with complete resection of enhancing disease (93{\%} complete resections among mutants vs 67{\%} among wild-type, P <. 001), indicating IDH1 mutant gliomas were more amenable to resection. The impact of residual tumor on survival differed between IDH1 wild-type and mutant tumors. Complete resection of enhancing disease among IDH1 wild-type tumors was associated with a median survival of 19.6 months versus 10.7 months for incomplete resection; however, no survival benefit was observed in association with further resection of nonenhancing disease (minimization of total tumor volume). In contrast, IDH1 mutants displayed an additional survival benefit associated with maximal resection of total tumor volume (median survival 9.75 y for >5 cc residual vs not reached for <5 cc, P =. 025).ConclusionsThe survival benefit associated with surgical resection differs based on IDH1 genotype in malignant astrocytic gliomas. Therapeutic benefit from maximal surgical resection, including both enhancing and nonenhancing tumor, may contribute to the better prognosis observed in the IDH1 mutant subgroup. Thus, individualized surgical strategies for malignant astrocytoma may be considered based on IDH1 status.",
keywords = "IDH1, anaplastic astrocytoma, glioblastoma, malignant glioma, surgical resection",
author = "Jason Beiko and Dima Suki and Hess, {Kenneth R.} and Fox, {Benjamin D.} and Vincent Cheung and Matthew Cabral and Shonka, {Nicole A} and Gilbert, {Mark R.} and Raymond Sawaya and Prabhu, {Sujit S.} and Jeffrey Weinberg and Lang, {Frederick F.} and Aldape, {Kenneth D.} and Sulman, {Erik P.} and Ganesh Rao and Mccutcheon, {Ian E.} and Cahill, {Daniel P.}",
year = "2014",
month = "1",
day = "1",
doi = "10.1093/neuonc/not159",
language = "English (US)",
volume = "16",
pages = "81--91",
journal = "Neuro-Oncology",
issn = "1522-8517",
publisher = "Oxford University Press",
number = "1",

}

TY - JOUR

T1 - IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection

AU - Beiko, Jason

AU - Suki, Dima

AU - Hess, Kenneth R.

AU - Fox, Benjamin D.

AU - Cheung, Vincent

AU - Cabral, Matthew

AU - Shonka, Nicole A

AU - Gilbert, Mark R.

AU - Sawaya, Raymond

AU - Prabhu, Sujit S.

AU - Weinberg, Jeffrey

AU - Lang, Frederick F.

AU - Aldape, Kenneth D.

AU - Sulman, Erik P.

AU - Rao, Ganesh

AU - Mccutcheon, Ian E.

AU - Cahill, Daniel P.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - BackgroundIDH1 gene mutations identify gliomas with a distinct molecular evolutionary origin. We sought to determine the impact of surgical resection on survival after controlling for IDH1 status in malignant astrocytomas - World Health Organization grade III anaplastic astrocytomas and grade IV glioblastoma.MethodsClinical parameters including volumetric assessment of preoperative and postoperative MRI were recorded prospectively on 335 malignant astrocytoma patients: n = 128 anaplastic astrocytomas and n = 207 glioblastoma. IDH1 status was assessed by sequencing and immunohistochemistry.ResultsIDH1 mutation was independently associated with complete resection of enhancing disease (93% complete resections among mutants vs 67% among wild-type, P <. 001), indicating IDH1 mutant gliomas were more amenable to resection. The impact of residual tumor on survival differed between IDH1 wild-type and mutant tumors. Complete resection of enhancing disease among IDH1 wild-type tumors was associated with a median survival of 19.6 months versus 10.7 months for incomplete resection; however, no survival benefit was observed in association with further resection of nonenhancing disease (minimization of total tumor volume). In contrast, IDH1 mutants displayed an additional survival benefit associated with maximal resection of total tumor volume (median survival 9.75 y for >5 cc residual vs not reached for <5 cc, P =. 025).ConclusionsThe survival benefit associated with surgical resection differs based on IDH1 genotype in malignant astrocytic gliomas. Therapeutic benefit from maximal surgical resection, including both enhancing and nonenhancing tumor, may contribute to the better prognosis observed in the IDH1 mutant subgroup. Thus, individualized surgical strategies for malignant astrocytoma may be considered based on IDH1 status.

AB - BackgroundIDH1 gene mutations identify gliomas with a distinct molecular evolutionary origin. We sought to determine the impact of surgical resection on survival after controlling for IDH1 status in malignant astrocytomas - World Health Organization grade III anaplastic astrocytomas and grade IV glioblastoma.MethodsClinical parameters including volumetric assessment of preoperative and postoperative MRI were recorded prospectively on 335 malignant astrocytoma patients: n = 128 anaplastic astrocytomas and n = 207 glioblastoma. IDH1 status was assessed by sequencing and immunohistochemistry.ResultsIDH1 mutation was independently associated with complete resection of enhancing disease (93% complete resections among mutants vs 67% among wild-type, P <. 001), indicating IDH1 mutant gliomas were more amenable to resection. The impact of residual tumor on survival differed between IDH1 wild-type and mutant tumors. Complete resection of enhancing disease among IDH1 wild-type tumors was associated with a median survival of 19.6 months versus 10.7 months for incomplete resection; however, no survival benefit was observed in association with further resection of nonenhancing disease (minimization of total tumor volume). In contrast, IDH1 mutants displayed an additional survival benefit associated with maximal resection of total tumor volume (median survival 9.75 y for >5 cc residual vs not reached for <5 cc, P =. 025).ConclusionsThe survival benefit associated with surgical resection differs based on IDH1 genotype in malignant astrocytic gliomas. Therapeutic benefit from maximal surgical resection, including both enhancing and nonenhancing tumor, may contribute to the better prognosis observed in the IDH1 mutant subgroup. Thus, individualized surgical strategies for malignant astrocytoma may be considered based on IDH1 status.

KW - IDH1

KW - anaplastic astrocytoma

KW - glioblastoma

KW - malignant glioma

KW - surgical resection

UR - http://www.scopus.com/inward/record.url?scp=84891544864&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84891544864&partnerID=8YFLogxK

U2 - 10.1093/neuonc/not159

DO - 10.1093/neuonc/not159

M3 - Article

VL - 16

SP - 81

EP - 91

JO - Neuro-Oncology

JF - Neuro-Oncology

SN - 1522-8517

IS - 1

ER -